Breakthrough in Glioblastoma Treatment with the Help of a Virus

Howard Colman, MD, PhD, was recently featured as an author on a publication in Nature Medicine describing the results of a recent clinical trial – a breakthrough in glioblastoma treatment with the help of a modified cold virus injected directly into the tumor. When combined with an immunotherapy drug, the authors observed a subset of patients that appeared to be living longer as a result of this therapy.

Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma

Henry Ford Cancer Institute is the first site in the world to activate two new treatments for glioblastoma (GBM), the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial known as GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).

Rutgers Cancer Institute Researchers Utilize 4D Printing with Patient Derived Organoids to Accelerate Treatment Testing for Common Brain Tumor

Rutgers Cancer Institute investigator shares about a new project in which 4-dimensional (4D) printing of arrays that transform from cell-culture inserts into histological cassettes are utilized and hold patient tissue samples for rapid programmable drug testing to accelerate treatment testing for glioblastoma multiforme (GBM), a common brain tumor.

Genome-wide pattern found in tumors from brain cancer patients predicts life expectancy

For the past 70 years, the best indicator of life expectancy for a patient with glioblastoma — the most common and the most aggressive brain cancer — has simply been age at diagnosis. Now, an international team of scientists has experimentally validated a predictor that is not only more accurate but also more clinically relevant: a pattern of co-occurring changes in DNA abundance levels, or copy numbers, at hundreds of thousands of sites across the whole tumor genome.